


PHARMACEUTICAL 2023

BENITEC BIOPHARMA silencing genes for life*

Benitec Biopharma Inc. Rank 409 of 446





PHARMACEUTICAL 2023

Benitec Biopharma Inc. Rank 409 of 446



The relative strengths and weaknesses of Benitec Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Benitec Biopharma Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Benitec Biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 265% points.

The company's Economic Capital Ratio, given in the ranking table, is -290%, being 333% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	4,820
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,532
Liabilities, Non-Current	559
Other Assets	931
Other Compr. Net Income	210
Other Expenses	9.0
Other Liabilities	0
Other Net Income	-354
Other Revenues	73
Property and Equipment	222
Research and Development	11,272
Selling, General and Administrative Expense	6,646

Output Variable	Value in 1000 USD
Assets	5,973
Liabilities	3,091
Expenses	17,927
Revenues	73
Stockholders Equity	2,882
Net Income	-18,208
Comprehensive Net Income	-18,103
Economic Capital Ratio	-290%

